Search
Close this search box.

IGC Pharma Reports Third Quarter Fiscal 2024 Results

POTOMAC, MD. February 16, 2024 / IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024). Q3 FY2024 Highlights On October 18, 2023, the European Patent Office (“EPO”) issued a patent (#3193862) to the Company titled […]

IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024

– IGC Pharma to Discuss AI Partnership and Initiatives at Biotech Showcase 2024 – POTOMAC, MD. December 13, 2023 / IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced that the Company’s management team will participate in Biotech Showcase and  BIO Partnering @ JPM, held in-person and scheduled alongside the J.P. Morgan […]

IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials

– IGC Pharma to Discuss AI Partnership and Initiatives at Biotech Showcase 2024 – POTOMAC, MD. December 6, 2023 / IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced an Artificial Intelligence (AI) collaboration with Los Andes University’s Center for Research and Training in Artificial Intelligence (“CINFONIA”). The partnership aims to leverage […]